Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-3167 in type 2 diabetes mellitus
NCT07018453Phase 2Active, not recruiting
- Sponsor
- Hengrui
- Start
- Jul 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SHR-3167 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Hengrui. Primary endpoint: Glycosylated Hemoglobin at 16 weeks. Started Jul 2025; status: active, not recruiting.
02
Drugs
SHR-3167
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07018453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018453.